Allergic Rhinitis and Hay Fever

The claim you will see everywhere is that butterbur works as well as an antihistamine for hay fever without making you drowsy. That claim is not invented — it comes from real randomised trials, published in the BMJ and elsewhere, comparing a standardised butterbur extract head-to-head with cetirizine and with fexofenadine. It is also considerably weaker than it sounds, for a reason that has nothing to do with herbs and everything to do with statistics: proving two treatments are equally good takes far more people than proving one beats a placebo, and these trials were small.

This article walks through each trial with its actual size, reports the negative and mixed results alongside the positive ones, and ends where every butterbur article has to end — with the pyrrolizidine-alkaloid ceiling that sits over the whole subject, and with a botanical irony that matters here more than anywhere else: butterbur is in the same plant family as ragweed.

Table of Contents

  1. What Allergic Rhinitis Is, and What Would Count as Working
  2. The Extract the Trials Used
  3. The Cetirizine Trial
  4. The Fexofenadine Trial
  5. The Dose-Finding Trial
  6. The Scottish Challenge Studies
  7. What Independent Reviewers Concluded
  8. Asthma: The Weakest Claim
  9. Leukotrienes: Why This Might Work
  10. Dose, Season Timing and What to Expect
  11. The Ragweed Problem
  12. Cautions and the Safety Ceiling
  13. The Honest Verdict
  14. Key Research Papers
  15. Connections
  16. Featured Videos

What Allergic Rhinitis Is, and What Would Count as Working

Allergic rhinitis is what happens when your immune system decides that grass pollen, tree pollen, ragweed, dust mite or cat dander is a threat. Immunoglobulin E (IgE) antibodies sitting on mast cells in the lining of your nose recognise the allergen, the mast cells rupture, and out comes a chemical cocktail — histamine first, then leukotrienes and prostaglandins over the following hours.

Those two waves produce different symptoms, which is why different drugs help with different complaints:

Butterbur’s pharmacology points at the second wave, which is a genuinely interesting place for a plant to act. Keep that in mind when reading the trials: an agent that works on leukotrienes should show up most clearly in blockage and congestion scores.

Trials of allergic rhinitis usually report a total nasal symptom score — sneezing, itching, running and blockage each rated on a small scale and added up — plus quality-of-life questionnaires. “Working” means a bigger fall in that score than placebo produces. Placebo produces a lot: people enrol when their symptoms peak, pollen counts move, and everyone improves on the calendar alone.

The Extract the Trials Used

Every positive allergic-rhinitis trial for butterbur used one preparation: a standardised butterbur leaf extract of Petasites hybridus whose tablets are labelled by their petasine content (the extract used in Schapowal 2002). It is not the same product as the migraine extract, it is not the same plant part, and it is not the same dose schedule.

This matters commercially. A capsule marketed in the United States as “butterbur for allergies” is very often the migraine-style root extract, or an unstandardised extract, sold on the strength of trials conducted with something else. When the research is this narrow — essentially one product, largely one investigator — the gap between “butterbur works” and “this bottle works” is wide enough to drive a truck through. See Choosing a PA-Free Product for how to tell the difference.

The Cetirizine Trial

Schapowal published this in the BMJ in 2002, and it is the study behind nearly every “as good as an antihistamine” headline.

Now the part that usually goes missing. There was no placebo arm. Without one, a trial in which two treatments improve equally cannot distinguish between “both work equally well” and “neither did much and everyone got better anyway.” And 125 people is far too few for an equivalence claim: with that many participants, a real difference of the size that would matter clinically could easily hide inside the statistical noise. “We failed to detect a difference” is not the same statement as “there is no difference,” and small trials fail to detect differences routinely.

The sedation finding is more solid, because it is a within-trial comparison of a known drug effect: cetirizine does cause drowsiness in a minority of users, butterbur apparently does not. For people whose problem with antihistamines is daytime drowsiness, that observation is genuinely relevant — though the trial report itself notes that cetirizine is considered a non-sedating antihistamine, and other second-generation antihistamines are described as essentially non-sedating.

The Fexofenadine Trial

The 2005 study in Phytotherapy Research is the stronger design, because it added the missing arm.

This is the single most useful piece of evidence butterbur has in allergy. It is properly blinded, it has a placebo comparator, and 330 people is a respectable size. The remaining limitations are the ones that apply to the whole literature: two weeks is short for a condition people live with for a whole season, and the trial — like all the others — used one extract.

The Dose-Finding Trial

Published in the Archives of Otolaryngology–Head & Neck Surgery in 2004, this study asked whether more extract does more.

Dose-response is one of the most persuasive patterns in pharmacology. Placebo effects and biased reporting do not usually produce a neat gradient in which more drug gives more effect; real pharmacological actions do. This trial is a big part of why the butterbur allergy story is taken seriously despite its narrowness.

The Scottish Challenge Studies

A separate group in Dundee ran a series of smaller, more mechanistic studies, and reporting them honestly means reporting a mixed picture.

One honest observation about this group of studies: they are small — crossover designs with a few dozen participants, powered to detect physiological signals rather than to establish clinical benefit. The overall pattern from Dundee is two positive nasal-challenge studies, one null clinical trial and a null skin study.

What Independent Reviewers Concluded

Guo, Pittler and Ernst reviewed the herbal-medicine evidence for allergic rhinitis in the Annals of Allergy, Asthma & Immunology in 2007 — a group with a long record of being unsparing about weak botanical claims. Butterbur emerged as among the better-supported herbal options for allergic rhinitis, while the review was clear that the evidence base overall was limited and that the encouraging results rested on a small number of trials of a single preparation. Six of its sixteen included trials studied butterbur, and the authors wrote that “independent replication is required before a firm conclusion can be drawn.”

That is a fair place to land. Butterbur is not in the same category as most herbal allergy remedies, which have essentially nothing. It is also not in the same category as intranasal corticosteroids, which have dozens of trials, tens of thousands of participants, and multiple independent manufacturers.

Two newer reviews have since been published. A 2024 systematic review and meta-analysis of single medicinal plants for allergic rhinitis included 29 randomised controlled trials (n = 1879); Petasites hybridus (butterbur) was the plant investigated most often (5 studies). On very-low-to-low-certainty evidence, single medicinal plants compared with placebo “may improve overall total nasal symptoms” (SMD -0.31, 95% CI -0.59 to -0.02; 5 studies), and moderate-certainty evidence showed no clear differences between them and antihistamines — results pooled across the plants, not for butterbur alone. The authors concluded: “Clear beneficial evidence of medicinal plants for allergic rhinitis is still lacking.”

A systematic review of European/Western phytotherapy and anthroposophic medicine in seasonal allergic rhinitis, published online in 2024, included 14 studies published between January 1990 and March 2023, about half of them rated as being of sufficient quality. Butterbur was the most frequently studied plant, “showing beneficial effects on immunological parameters, subjective symptoms, and nasal airflow.”

Asthma: The Weakest Claim

You will occasionally see butterbur recommended for asthma. The evidence for that is thin enough to state in one paragraph.

Danesch published an open trial of butterbur root extract — not the leaf extract of the rhinitis trials — in asthma in Alternative Medicine Review in 2004. It was prospective and non-randomised: 64 adults and 16 children and adolescents took the extract for two months, followed by two months in which taking it was optional, and their usual asthma medication was permitted throughout. Participants knew what they were taking, and there was no control group. Asthma symptoms and peak-flow readings fluctuate with season, adherence, infection and attention — all of which improve in anyone enrolled in a study and asked to keep a diary. An uncontrolled asthma study cannot separate a drug effect from any of that.

Asthma is also a condition where getting it wrong is dangerous. Under-treated airway inflammation kills people, and substituting an unproven botanical for inhaled corticosteroids is one of the classic routes to a preventable asthma death. The one asthma trial let participants keep their usual asthma medication, so it tells nothing about butterbur used in its place.

Leukotrienes: Why This Might Work

The pharmacological case for butterbur in allergy is more coherent than the case in migraine.

Laboratory work by Thomet and colleagues found that a butterbur extract suppressed leukotriene production in human inflammatory cells, and that petasin accounted for a large share of that activity. Leukotrienes are exactly the mediators responsible for the nasal blockage and swelling that antihistamines handle badly. A follow-up review by the same group summarised the preclinical and clinical picture for petasins in allergic disease.

So the chain of reasoning is: butterbur contains petasin → petasin inhibits leukotriene synthesis → leukotrienes cause nasal congestion → butterbur should reduce nasal congestion. Each link has support, and the clinical trials are broadly consistent with the prediction. That coherence is genuinely reassuring. It is still not proof: nobody has shown that butterbur relieves human hay fever by inhibiting leukotrienes, and all the mechanistic work is cell-culture, not human.

It is worth noting the pharmacological company this puts butterbur in. Montelukast is a leukotriene-receptor antagonist — a well-characterised prescription drug that works on the same pathway, is available cheaply as a generic, and carries its own (neuropsychiatric) warnings.

Dose, Season Timing and What to Expect

Again: information, not a recommendation. The liver-safety facts are set out in the Pyrrolizidine Alkaloids and Liver Safety article.

ElementWhat the trials usedNotes
PreparationA standardised butterbur leaf extract certified free of pyrrolizidine alkaloids, labelled by petasine contentNot the migraine root extract, and not an unstandardised capsule
ScheduleOne tablet two to four times dailyFrequent dosing — this is a short-acting agent, unlike a once-daily antihistamine
Dose-responseOne tablet three times daily outperformed one tablet twice dailyThe dose-finding trial; higher doses have not been tested for safety over a season
Trial durationTwo weeksThe whole rhinitis literature is short-term. A three-month pollen season is unstudied territory
Symptoms most likely to respondNasal blockage and congestionFollows from the leukotriene mechanism
SedationNot observedThe most defensible advantage over first-generation and some second-generation antihistamines

Practical realities. Butterbur is short-acting and needs dosing several times a day, which most people manage badly. Its commonest side effects are gastrointestinal — burping with a distinctive and unpleasant taste, mild nausea, stomach upset. It costs considerably more than a generic antihistamine. And the trial evidence covers two weeks, while hay fever season runs for months, so anyone using it across a full season is extrapolating well beyond the data — which is exactly the situation the liver-safety concern makes uncomfortable.

Set against the standard toolkit: intranasal corticosteroids are the most effective single treatment for allergic rhinitis and act on congestion better than anything else here; saline rinses are free, harmless and genuinely useful; second-generation antihistamines are cheap, once-daily and mostly non-sedating; and montelukast targets the same leukotriene pathway butterbur aims at, with a prescriber supervising. That is the list butterbur is measured against.

Longer use has been followed in an observational study without a comparison group. In a 2021 noninterventional observational study of the same leaf extract, data from 226 Swiss outpatients were collected over a mean of 63 days, with 75% treated for at least 4 weeks; 58.5% took the extract alone and 41.5% also received other anti-allergy and/or decongestant drugs. Allergic and inflammatory symptom scores fell significantly (p < 0.001) and quality-of-life scores improved, and three mild gastrointestinal adverse events occurred. Every patient received the extract, so the study cannot separate its effect from the season or other treatment.

The Ragweed Problem

This deserves its own section, because it is a specific hazard that applies to this indication more than any other.

Butterbur belongs to the Asteraceae — the daisy or composite family. So do ragweed, chrysanthemum, marigold, daisy, chamomile, echinacea, arnica, dandelion and feverfew. Members of this family share allergenic proteins and, in contact allergy, share sesquiterpene lactone allergens; reviews of allergy to Asteraceae medicinal plants describe exactly this pattern of cross-sensitisation.

The irony is sharp. Ragweed is one of the leading causes of seasonal allergic rhinitis in North America. Someone with bad autumn hay fever is therefore disproportionately likely to be ragweed-sensitised — and is being offered a remedy from ragweed’s own botanical family. It is entirely possible to take a butterbur product for hay fever and have an allergic reaction to it.

People who react to ragweed, chrysanthemums, marigolds, daisies, chamomile or echinacea are the group in whom this cross-sensitisation raises a concern. Reactions can range from worsened rhinitis and itching to rash to, rarely, more serious allergic responses. A pharmacological detail worth knowing: the petasins are sesquiterpene esters, chemically distinct from the sesquiterpene lactones that cause classic Compositae contact dermatitis — but a plant extract contains far more than its marker compound, so this distinction does not rule out a reaction.

Cautions and the Safety Ceiling

Everything in this article sits underneath the ceiling described in Pyrrolizidine Alkaloids and Liver Safety. The short version, allergy-specific:

The Honest Verdict

Back to Table of Contents

Key Research Papers

Every identifier below was verified live against the NCBI PubMed database — title, first author, journal and year all had to match. Study type and size are stated where known, and the limitations are stated with the results.

The randomised trials

  1. Schapowal A. Treating intermittent allergic rhinitis: a prospective, randomized, placebo and antihistamine-controlled study of butterbur extract Ze 339. Phytotherapy Research. 2005;19(6):530–537 — PubMed PMID: 16114089 — Human randomised trial, 330 participants, two weeks; butterbur and fexofenadine both improved symptoms versus placebo and were comparable to each other. The best single piece of evidence butterbur has in allergy.
  2. Schapowal A. Butterbur Ze339 for the treatment of intermittent allergic rhinitis: dose-dependent efficacy in a prospective, randomized, double-blind, placebo-controlled study. Archives of Otolaryngology–Head & Neck Surgery. 2004;130(12):1381–1386 — PubMed PMID: 15611396 — Human randomised trial, 186 participants; dose-dependent benefit over placebo — the dose-response pattern is the most persuasive feature of this literature.
  3. Schapowal A. Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis. BMJ. 2002;324(7330):144–146 — PubMed PMID: 11799030 — Human randomised trial, 125 participants, two weeks; similar SF-36 and global-impression scores to cetirizine, with two thirds (8/12) of the cetirizine group’s adverse events sedative. No placebo arm, and far too small to establish equivalence.

Objective and mechanistic studies from an independent group

  1. Lee DK, Carstairs IJ, Haggart K, Jackson CM, Currie GP, Lipworth BJ. Butterbur, a herbal remedy, attenuates adenosine monophosphate induced nasal responsiveness in seasonal allergic rhinitis. Clinical and Experimental Allergy. 2003;33(7):882–886 — PubMed PMID: 12859442 — Small human challenge study using an objective provocation test rather than symptom diaries.
  2. Lee DK, Gray RD, Robb FM, Fujihara S, Lipworth BJ. A placebo-controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis. Clinical and Experimental Allergy. 2004;34(4):646–649 — PubMed PMID: 15080820 — Small crossover study in year-round, not seasonal, allergic rhinitis.
  3. Gray RD, Haggart K, Lee DK, Cull S, Lipworth BJ. Effects of butterbur treatment in intermittent allergic rhinitis: a placebo-controlled evaluation. Annals of Allergy, Asthma & Immunology. 2004;93(1):56–60 — PubMed PMID: 15281472 — Small placebo-controlled crossover evaluation, 35 patients; no significant effect versus placebo on any outcome.
  4. Jackson CM, Lee DK, Lipworth BJ. The effects of butterbur on the histamine and allergen cutaneous response. Annals of Allergy, Asthma & Immunology. 2004;92(2):250–254 — PubMed PMID: 14989395 — Skin-response study, 20 patients — a different readout from nasal symptoms, and not a clinical efficacy trial; butterbur had no significant effect versus placebo.

Independent review, and the asthma question

  1. Guo R, Pittler MH, Ernst E. Herbal medicines for the treatment of allergic rhinitis: a systematic review. Annals of Allergy, Asthma & Immunology. 2007;99(6):483–495 — PubMed PMID: 18219828 — Independent systematic review; butterbur among the better-supported herbal options, on a limited evidence base tied to one preparation.
  2. Danesch UC. Petasites hybridus (butterbur root) extract in the treatment of asthma — an open trial. Alternative Medicine Review. 2004;9(1):54–62 — PubMed PMID: 15005644 — Open, uncontrolled trial. Cannot separate treatment effect from natural fluctuation, and asthma is not a condition in which to accept weak evidence.
  3. Lim XY, Lau MS, Zolkifli NA, Sastu Zakaria UR, Mohd Rahim NS, Lai NM, Tan TYC. Medicinal plants for allergic rhinitis: A systematic review and meta-analysis. PLoS One. 2024;19(4):e0297839 — PubMed PMID: 38603736 — Systematic review and meta-analysis, 29 randomised trials (n = 1879); butterbur the most-studied plant (5 studies); very-low-to-low-certainty evidence of benefit over placebo across plants.
  4. Braunwalder C, Ertl J, Wullschleger M, Timm E, Wolf U. Efficacy and Safety of Phytotherapy and Anthroposophic Medicine in Seasonal Allergic Rhinitis: A Systematic Review. International Archives of Allergy and Immunology. 2025;186(1):75–86 — PubMed PMID: 39084196 — Systematic review, 14 studies (1990 to March 2023); butterbur the most frequently studied plant.
  5. Blosa M, Uricher J, Nebel S, Zahner C, Butterweck V, Drewe J. Treatment of Early Allergic and Late Inflammatory Symptoms of Allergic Rhinitis with Petasites hybridus Leaf Extract (Ze 339): Results of a Noninterventional Observational Study in Switzerland. Pharmaceuticals. 2021;14(3):180 — PubMed PMID: 33668395 — Observational study without a comparison group, 226 outpatients, mean 63 days.

Pharmacology of the petasins

  1. Thomet OA, Wiesmann UN, Schapowal A, Bizer C, Simon HU. Role of petasin in the potential anti-inflammatory activity of a plant extract of Petasites hybridus. Biochemical Pharmacology. 2001;61(8):1041–1047 — PubMed PMID: 11286996 — Cell-culture study identifying petasin as the principal driver of leukotriene suppression.
  2. Thomet OA, Simon HU. Petasins in the treatment of allergic diseases: results of preclinical and clinical studies. International Archives of Allergy and Immunology. 2002;129(2):108–112 — PubMed PMID: 12403927 — Review linking the laboratory pharmacology to the clinical results.

Asteraceae allergy and cross-reactivity

  1. Ključevšek T, Kreft S. Allergic potential of medicinal plants from the Asteraceae family. Health Science Reports. 2025;8(2):e70398 — PubMed PMID: 39995792 — Review of allergy risk across the daisy family — the family butterbur, ragweed, chamomile and feverfew all belong to.
  2. Denisow-Pietrzyk M, Pietrzyk Ł, Denisow B. Asteraceae species as potential environmental factors of allergy. Environmental Science and Pollution Research International. 2019;26(7):6290–6300. — PubMed PMID: 30666578

PubMed Topic Searches

  1. PubMed: Standardised butterbur leaf extract and allergic rhinitis
  2. PubMed: Butterbur and hay fever
  3. PubMed: Petasites hybridus rhinitis
  4. PubMed: Petasin and leukotriene inhibition
  5. PubMed: Leukotrienes and nasal congestion
  6. PubMed: Intranasal corticosteroids for rhinitis
  7. PubMed: Ragweed and Asteraceae cross-reactivity
  8. PubMed: Herbal medicines for allergic rhinitis

Connections


Back to Table of Contents